SEC Tracker
Get the app

Valion Bio

VBIO

Jun 30, 2026 figures: 1 month of cash, which would have lasted to Aug 2026; next 10-Q due Nov 16, 2026; raised since: Oct 27, 2026 8-K from the 10-Q on EDGAR

Get email alertsGet the app
Legal name
Valion Bio, Inc.
CIK
1787740
Sector
Biotech and pharma

Latest Valion Bio’s latest filing is an 8-K from . Every Valion Bio filing is below, newest first.

Dilution Known so far: no new shares beyond today's 22.2M · shelf room about $1.3M · not yet read: warrants, converts, options, ATM; 59.8M registered for resale, not counted. Every source

Insiders No open-market insider buys or sells at Valion Bio in the last 90 days; 4 filings reported awards, option exercises, tax withholding or new insiders. Every trade

Major8-K filed

Valion Bio announces executive separation

  • Melinda Lackey received $26,750 severance payment
  • Company will pay COBRA premiums until November 30, 2026
  • Separation Agreement includes confidentiality and non-disparagement clauses

Read the 8-K on EDGARTables over time

IPO registration

Priced and listed · DRS filed Oct 5, 2026

  1. Registration declared effective EFFECT
  2. Registration declared effective EFFECT
  3. Draft registration, filed confidentially DRSFirst filing

Cash runway and key numbers

About 1 month of cash at the average operating burn of the last 2 quarters. At that burn, cash would have lasted to Aug 2026; next 10-Q due Nov 16, 2026. Since then: $26,750 raised on Nov 2 (8-K).

Cash
$2.1M
Operating burn a quarter, average of the last 2 quarters
$5.1M

From the 10-Q 0001437749-26-028069 for the period ended Jun 30, 2026, as tagged in its XBRL. An estimate from reported figures, not a forecast or advice.

Every line item over time, with Excel and CSV export

Get an email when Valion Bio files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What Valion Bio does

Products

  • Entolimod In development

    A recombinant TLR5 agonist for acute radiation syndrome and oncology indications. Source

    Segment: Biopharma

    • FDA: investigational, Animal Rule Source

  • Entolasta In development

    A second-generation TLR5 agonist developed to address the immunogenicity of Entolimod. Source

    Segment: Biopharma

Headquarters
San Antonio, TX Source

From the 10-K filed Mar 30, 2026, Item 1, Business (its first part). Open the filing. Each line links to the passage it restates. The company's own description, summarized; not investment advice.

All filings

Results, 8-Ks and Major or Notable filings come first, then registrations and share actions, then everything else, newest first. Routine filings are kept here unmarked; insider filings are summed up in one line.

Results, 8-Ks and key filings

  9. 14 older filings, Sep 23 to Jun 3

No open-market insider buys or sells at Valion Bio in the last 90 days; 4 filings reported awards, option exercises, tax withholding or new insiders. Every VBIO insider trade

Financing and share filings

  9. 6 older filings, Sep 1 to Jun 18

Other filings

  9. 1 older filing, Jun 5

Older filings on EDGAR

Shares registered for resale

Known so far: no new shares beyond today's 22.2M · shelf room about $1.3M · not yet read: warrants, converts, options, ATM.

59.8M registered for resale, already counted in today's shares where issued; 19.7M of them likely already outstanding.

Not read yet: warrants, convertible notes, options and RSUs and an ATM program.

What could become new VBIO shares

Listing compliance

0 open of 1 listing notice from 8-K item 3.01.

  • Mar 20, 2026 8-K item 3.01 notice; rule and cure date not stated, see the filing

Dates and rules are as stated in each 8-K item 3.01 filing; a blank means the filing did not state one. Read the filing for the full terms. All open notices

Trading halts

No trading halts for VBIO since Feb 22, 2019, when SEC Tracker began reading the Nasdaq Trader feed.

Halt times and codes from the Nasdaq Trader trade halts feed, which lists Nasdaq and other exchange halts. Filings matched by SEC Tracker from EDGAR by company and time. Not investment advice. All recent halts

Fails-to-deliver: 9,687 shares on Aug 27, 2026, per SEC data

Coming up

  1. Earnings, expected
  2. 10-Q, expected (deadline Nov 16)

Stated dates are as each filing on EDGAR gives them; an expected date is estimated from the company's past filing dates, the same estimate as the top of the page. Not investment advice.

Valion Bio shares and listing

From the company's own filings; each row names its source. Not investment advice.

  • Shares outstandingas of Aug 13, 2026 (10-Q filed Aug 14)22.2Mwarrants, notes and options not read yet, so fully diluted is not known
  • Listing compliance8-K item 3.011 noticestatus not stated, see the filings

Insider activity

No open-market insider buys or sells at Valion Bio in the last 90 days; 4 filings reported awards, option exercises, tax withholding or new insiders.

All VBIO insider trades